The Research Group Dietrich is a Partner group of the European Molecular Biology Laboratory (EMBL) within the Molecular Medicine Partnership Unit (MMPU):

Our aim is to bring biology-based individualized treatment of lymphoma and leukemia into clinical practice. To achieve this ambitious aim, we establish a systems medicine program that integrates systematic functional assays, multi-omic profiling, bioinformatic analysis, mathematical modeling and setup towards a clinical exploitation. The basis of the program is a platform to map patient specific pathway activity and drug sensitivity of their primary tumor cells ex-vivo. By comparing drug responses across patients with detailed molecular characterization (e.g. whole exome- and RNA-sequencing) and the clinical parameters, we obtain a rich set of associations of drug sensitivity with biology, biomarkers and outcome.

Figure 1) The general layout of our research program.

A particular focus of our research is on signals provided by the microenvironment, and how these signals modify pathway activities targeted by drugs. We aim to generate a systems-level understanding of how the microenvironment and the individual genetic and molecular make-up of a tumor interact and modify drug response using a high throughput automated microscopy platform mimicking microenvironment conditions. In parallel, we investigate further dimensions of in-vivo drug response (3D-space, timing of drug response) with a hierarchy of increasingly complex culture models and readouts in suitable tumors.

Our group is funded by the eMed Programm of the BMBF. (http://www.sys-med.de/de/)


Cell line drug screen

Tobias Roider

Proteogenomics and drug response of CLL

Sophie Herbst

Cell line combination screen

Tobias Roider

Single Cell Lymphoma Explorer

Dr. Simon Anders

CLL drug-microenvironment interactions

Peter-Martin Bruch and Holly Giles

Our Team




{{member.mail}} {{member.tel}} {{member.tel2}}



{{pub.title}} {{pub.authors}} {{pub.journal}} PMID: {{pub.pmid}}